

Development of Preclinical Candidates Targeting Novel TAS2R GPCR for Parkinson's disease



NEUROLOGY	Candidate
Product Type	Small molecule
Indication	Parkinson's disease
Target	TAS2R GPCR
MoA(Mechanism of Action)	The TAS2R agonist suppresses neuroinflammation and promotes neuronal survival, neurogenesis, and dopaminergic function, providing neuroprotective benefits in Parkinson's disease.
Competitiveness	TAS2R agonists show potent neuroprotective and neuroregenerative effects with strong efficacy in Parkinson's models, and their favorable ADME and safety profiles highlight high competitiveness as disease-modifying therapy candidates.
Development Stage	Candidate
Route of Administration	Oral administration

Any unauthorized distribution or reproduction of this material is strictly prohibited.